tbuckley/cabot-search huggingface dataset:
Usefulness of red dichromatic imaging for post-endoscopic sphincterotomy bleeding
Authors: Tadahisa Inoue, Mayu Ibusuki, Rena Kitano, Yuji Kobayashi, Kiyoaki Ito, Masashi Yoneda
Journal: Endoscopy (2022)

Endoscopic sphincterotomy (ES) is a crucial procedure in the treatment of biliary disease, but post-ES bleeding is an occasional adverse event [1]. Massive bleeding makes it difficult to continue the procedure, including hemostasis, because of poor visibility due to coagulum, the narrowness of the duodenum, and technical difficulty of using a side-viewing endoscope. Red dichromatic imaging, a recently developed novel image-enhanced endoscopy technology with good visualization of bleeding points and deep vessels, has been reported to be useful in various situations during upper and lower gastrointestinal endoscopy [2] [3] [4] [5]. Herein we present a case in which red dichromatic imaging was useful for hemostasis of massive post-ES bleeding.
Italian Constitution amended to include environmental and health protection: A model for Europe
Authors: Prisco Piscitelli, Sergio Costa, Andrea Costa, Michele Emiliano, Nicola Caputo, Francesco Schittulli, Marco Bonabello, Fabio Pollice, Antonio Felice Uricchio, Alfonso Pecoraro Scanio, Alessandro Miani
Journal: The Lancet Regional Health - Europe (2022)
TCTAP A-012 First Report on 30-Day Outcomes of Patients Treated With DynamX Bioadaptor Drug-Eluting Stent in Primary Percutaneous Coronary Intervention
Authors: Hee Hwa Ho, Ki Fung Cliff Li, Jun Bang Low, Thet Khaing, Jinhyun Lee, Deanna Zin Lin Khoo, Jason Kwok Kong Loh, Fahim Haider Jafary
Journal: Journal of the American College of Cardiology (2022)
Monkeypox in a Traveler Returning from Nigeria — Dallas, Texas, July 2021
Authors: Agam K. Rao, Joann Schulte, Tai-Ho Chen, Christine M. Hughes, Whitni Davidson, Justin M. Neff, Mary Markarian, Kristin C. Delea, Suzanne Wada, Allison Liddell, Shane Alexander, Brittany Sunshine, Philip Huang, Heidi Threadgill Honza, Araceli Rey, Benjamin Monroe, Jeffrey Doty, Bryan Christensen, Lisa Delaney, Joel Massey, Michelle Waltenburg, Caroline A. Schrodt, David Kuhar, Panayampalli S. Satheshkumar, Ashley Kondas, Yu Li, Kimberly Wilkins, Kylie M. Sage, Yon Yu, Patricia Yu, Amanda Feldpausch, Jennifer McQuiston, Inger K. Damon, Andrea M. McCollum, Asma’u Aminu-Alhaji, Lauren Andersen, Matthew Arduino, Nicolette Bestul, Megan Bias, Mary J. Choi, Crystal Gigante, Madison Harkey, Kate Hendricks, Yonette Hercules, Farah Husain, Oladipupo Ipadeola, Robynne Jungerman, Theodora Khan, Grishma Kharod, Amber Kunkel, Amanda MacGurn, Audrey Matheny, Timothy McCleod, Faisal S. Minhaj, Jenna Mink, Clint Morgan, Yoshinori Nakazawa, Donovan Newton, Eddy Ortega, Lalita Priyamvada, Kay Radford, Joseph Rehfus, Muhammad Muhammad Saleh, Michael B. Townsend, Rita Traxler, Florence Whitehill, Xianfu Wu, Hui Zhao, Michelle Carruthers, Ivory Gomez, Samantha Groppell, Juan Jaramillo, Daniel Serinaldi, Jose Serrano, Joey Stringer, Jenna Gettings, Jessica Pavlick, José David Retana, Shelley Stonecipher, Rachael Straver, Inger-Marie Vilcins, Leisha D. Nolen
Journal: MMWR Morbidity and Mortality Weekly Report (2022)

Response TeamMonkeypox is a rare, sometimes life-threatening zoonotic infection that occurs in west and central Africa.It is caused by Monkeypox virus, an orthopoxvirus similar to Variola virus (the causative agent of smallpox) and Vaccinia virus (the live virus component of orthopoxvirus vaccines) and can spread to humans.After 39 years without detection of human disease in Nigeria, an outbreak involving 118 confirmed cases was identified during 2017-2018 (1); sporadic cases continue to occur.During September 2018-May 2021, six unrelated persons traveling from Nigeria received diagnoses of monkeypox in non-African countries: four in the United Kingdom and one each in Israel and Singapore.In July 2021, a man who traveled from Lagos, Nigeria, to Dallas, Texas, became the seventh traveler to a non-African country with diagnosed monkeypox.Among 194 monitored contacts, 144 (74%) were flight contacts.The patient received tecovirimat, an antiviral for treatment of orthopoxvirus infections, and his home required large-scale decontamination.Whole genome sequencing showed that the virus was consistent with a strain of Monkeypox virus known to circulate in Nigeria, but the specific source of the patient's infection was not identified.No epidemiologically linked cases were reported in Nigeria; no contact received postexposure prophylaxis (PEP) with the orthopoxvirus vaccine ACAM2000.† https://wwwnc.cdc.gov/travel/destinations/traveler/none/nigeria?s_cid%20 =%20ncezid-dgmq-travel-single-001
National tuberculosis spending efficiency and its associated factors in 121 low-income and middle-income countries, 2010–19: a data envelopment and stochastic frontier analysis
Authors: Gerard Joseph Abou Jaoude, Ines Garcia Baena, Peter Nguhiu, Andrew Siroka, Tom Palmer, Lara Goscé, Kasim Allel, Edina Sinanovic, Jolene Skordis, Hassan Haghparast-Bidgoli
Journal: The Lancet Global Health (2022)

Maximising the efficiency of national tuberculosis programmes is key to improving service coverage, outcomes, and progress towards End TB targets. We aimed to determine the overall efficiency of tuberculosis spending and investigate associated factors in 121 low-income and middle-income countries between 2010 and 2019.In this data envelopment and stochastic frontier analysis, we used data from the WHO Global TB report series on tuberculosis spending as the input and treatment coverage as the output to estimate tuberculosis spending efficiency. We investigated associations between 25 independent variables and overall efficiency.We estimated global tuberculosis spending efficiency to be between 73·8% (95% CI 71·2-76·3) and 87·7% (84·9-90·6) in 2019, depending on the analytical method used. This estimate suggests that existing global tuberculosis treatment coverage could be increased by between 12·3% (95% CI 9·4-15·1) and 26·2% (23·7-28·8) for the same amount of spending. Efficiency has improved over the study period, mainly since 2015, but a substantial difference of 70·7-72·1 percentage points between the most and least efficient countries still exists. We found a consistent significant association between efficiency and current health expenditure as a share of gross domestic product, out-of-pocket spending on health, and some Sustainable Development Goal (SDG) indicators such as universal health coverage.To improve efficiency, treatment coverage will need to be increased, particularly in the least efficient contexts where this might require additional spending. However, progress towards global End TB targets is slow even in the most efficient countries. Variables associated with TB spending efficiency suggest efficiency is complimented by commitments to improving health-care access that is free at the point of use and wider progress towards the SDGs. These findings support calls for additional investment in tuberculosis care.None.
Therapeutic Value Assessments of Novel Medicines in the US and Europe, 2018-2019
Authors: Kerstin N. Vokinger, Thomas J. Hwang, Camille E. G. Glaus, Aaron S. Kesselheim
Journal: JAMA Network Open (2022)

This economic evaluation study assesses the clinical benefit of novel drugs approved in 2018 and 2019 and examines whether drugs approved with special regulatory designations appear to provide meaningful therapeutic value.
Downstream Mammary and Extramammary Cascade Services and Spending Following Screening Breast Magnetic Resonance Imaging vs Mammography Among Commercially Insured Women
Authors: Ishani Ganguli, Nancy L. Keating, Nitya Thakore, Joyce Lii, Sughra Raza, Lydia E. Pace
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Increasing use of screening breast magnetic resonance imaging (MRI), including among women at low or average risk of breast cancer, raises concerns about resulting mammary and extramammary cascades (downstream services and new diagnoses) of uncertain value. <h3>Objective</h3> To estimate rates of cascade events (ie, laboratory tests, imaging tests, procedures, visits, hospitalizations, and new diagnoses) and associated spending following screening breast MRI vs mammography among commercially insured US women. <h3>Design, Setting, and Participants</h3> This cohort study used 2016 to 2018 data from the MarketScan research database (IBM Corporation), which includes claims and administrative data from large US employers and commercial payers. Participants included commercially insured women aged 40 to 64 years without prior breast cancer who received an index bilateral screening breast MRI or mammogram between January 1, 2017, and June 30, 2018. We used propensity scores based on sociodemographic, clinical, and utilization variables to match MRI recipients to mammogram recipients in each month of index service use. Data were analyzed from October 8, 2020, to October 28, 2021. <h3>Exposures</h3> Breast MRI vs mammography. <h3>Main Outcomes and Measures</h3> Mammary and extramammary cascade event rates and associated total and patient out-of-pocket spending in the 6 months following the index test. <h3>Results</h3> In this study, 9208 women receiving breast MRI were matched with 9208 women receiving mammography (mean [SD] age, 51.4 [6.7] years). Compared with mammogram recipients, breast MRI recipients had 39.0 additional mammary cascade events per 100 women (95% CI, 33.7-44.2), including 5.0 additional imaging tests (95% CI, 3.8-6.2), 17.3 additional procedures (95% CI, 15.5-19.0), 13.0 additional visits (95% CI, 9.4-17.2), 0.34 additional hospitalizations (95% CI, 0.18-0.50), and 3.0 additional new diagnoses (95% CI, 2.5-3.6). For extramammary cascades, breast MRI recipients had 19.6 additional events per 100 women (95% CI, 8.6-30.7) including 15.8 additional visits (95% CI, 10.2-21.4) and no statistically significant differences in other events. Breast MRI recipients had higher total spending for mammary events ($564 more per woman; 95% CI, $532-$596), extramammary events ($42 more per woman; 95% CI, $16-$69), and overall ($1404 more per woman; 95% CI, $1172-$1636). They also had higher overall out-of-pocket spending ($31 more per woman; 95% CI, $6-$55). <h3>Conclusions and Relevance</h3> In this cohort study of commercially insured women, breast MRI was associated with more mammary and extramammary cascade events and spending relative to mammography. These findings can inform cost-benefit assessments and coverage policies to ensure breast MRI is reserved for patients for whom benefits outweigh harms.
Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study
Authors: Ioannis Katsoularis, Osvaldo Fonseca-Rodríguez, Paddy Farrington, Hanna Jerndal, Erling Häggström Lundevaller, Malin Sund, Krister Lindmark, Anne-Marie Fors Connolly
Journal: BMJ (2022)

Abstract Objective To quantify the risk of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19. Design Self-controlled case series and matched cohort study. Setting National registries in Sweden. Participants 1 057 174 people who tested positive for SARS-CoV-2 between 1 February 2020 and 25 May 2021 in Sweden, matched on age, sex, and county of residence to 4 076 342 control participants. Main outcomes measures Self-controlled case series and conditional Poisson regression were used to determine the incidence rate ratio and risk ratio with corresponding 95% confidence intervals for a first deep vein thrombosis, pulmonary embolism, or bleeding event. In the self-controlled case series, the incidence rate ratios for first time outcomes after covid-19 were determined using set time intervals and the spline model. The risk ratios for first time and all events were determined during days 1-30 after covid-19 or index date using the matched cohort study, and adjusting for potential confounders (comorbidities, cancer, surgery, long term anticoagulation treatment, previous venous thromboembolism, or previous bleeding event). Results Compared with the control period, incidence rate ratios were significantly increased 70 days after covid-19 for deep vein thrombosis, 110 days for pulmonary embolism, and 60 days for bleeding. In particular, incidence rate ratios for a first pulmonary embolism were 36.17 (95% confidence interval 31.55 to 41.47) during the first week after covid-19 and 46.40 (40.61 to 53.02) during the second week. Incidence rate ratios during days 1-30 after covid-19 were 5.90 (5.12 to 6.80) for deep vein thrombosis, 31.59 (27.99 to 35.63) for pulmonary embolism, and 2.48 (2.30 to 2.68) for bleeding. Similarly, the risk ratios during days 1-30 after covid-19 were 4.98 (4.96 to 5.01) for deep vein thrombosis, 33.05 (32.8 to 33.3) for pulmonary embolism, and 1.88 (1.71 to 2.07) for bleeding, after adjusting for the effect of potential confounders. The rate ratios were highest in patients with critical covid-19 and highest during the first pandemic wave in Sweden compared with the second and third waves. In the same period, the absolute risk among patients with covid-19 was 0.039% (401 events) for deep vein thrombosis, 0.17% (1761 events) for pulmonary embolism, and 0.101% (1002 events) for bleeding. Conclusions The findings of this study suggest that covid-19 is a risk factor for deep vein thrombosis, pulmonary embolism, and bleeding. These results could impact recommendations on diagnostic and prophylactic strategies against venous thromboembolism after covid-19.
Randomized Trial of a Supportive Psychotherapy for Parents of Adolescents and Young Adults With Hematologic Malignancies
Authors: Michael Koehler, Susanne Hoppe, Siegfried Kropf, Anke Lux, Rainer Bartsch, Bernhard Holzner, Juergen Krauter, Axel Florschütz, Kathleen Jentsch-Ullrich, Joerg Frommer, Hans-Henning Flechtner, Thomas Fischer
Journal: Journal of the National Comprehensive Cancer Network (2022)

Background: Cancer regularly disrupts health and developmental trajectories in adolescents and young adults (AYAs). Parents have been shown to have a substantial impact on the health and cancer survivorship activities of AYA patients in the form of symptom management. However, no randomized controlled trial has evaluated a coping support intervention (CSI) program for parents of AYAs with cancer aged 18 to 40 years. Patients and Methods: From November 30, 2012, to August 29, 2016, parents of AYAs with hematologic malignancies were randomized in a phase III controlled trial (1:1 ratio, stratified sampling) to either the research-based CSI AYA-Parents group (CSI group; n=82) or the standard care (SC) group (n=70). CSI consisted of 5 sessions to achieve the enhancement of parental adaptive coping as the primary outcome (per the adaptive coping scale of the 28-item Brief COPE, a validated multidimensional self-assessment-questionnaire recommended for clinical cancer research). Measures of adaptive coping, depression, and mental health were collected at pre-CSI (measurement date T1), at the end of the intervention sessions (measurement date T2), and at follow-up (3 months). We calculated mean change scores in outcomes and estimated intervention effect sizes (Cohen’s d ) for changes from T1 to T2/T3, with 0.2 indicating a small effect, 0.5 a medium effect, and 0.8 a large effect. All statistical tests were 2-sided. Results: In the intention-to-treat analysis, the CSI group significantly improved their adaptive coping compared with the SC group (95% CI, 0.30–2.54; P =.013; d =0.405), whereas adaptive coping in the SC group deteriorated. The CSI group also experienced a significant decrease in depressive symptoms and improved mental health with clinical significance (95% CI, –1.98 to –0.30; P =.008; d =0.433, and 95% CI, –0.19 to 3.97; P =.074; d =0.292, respectively). Sensitivity analyses confirmed the robustness of the main intention-to-treat analysis. Conclusions: CSI improved effectively adaptive coping and depression in parents of AYAs with hematologic malignancies. It may represent a novel family-based approach in AYA oncology care.
Inadequate protection against measles and rubella among pregnant women in Greece during the last measles outbreak
Authors: S. Papailiou, A. Soldatou, A. Marmarinos, M. Avgeris, E. Papathoma, M. Sindos, S. Georgantzi, Α. Rodolakis, N. Iacovidou, D. Gourgiotis, M. Tsolia
Journal: Journal of Infection (2022)
TCTAP A-046 Prognostic Impact of Plasma Glucose on Cardiogenic Shock Patients With or Without Diabetes Mellitus: Smart Rescue Trial
Authors: Seong Huan Choi, Gwang-Seok Yoon, Sang-Don Park, Young-Guk Ko, Chul-Min Ahn, Cheol Woong Yu, Hyun-Joong Kim, Bum Sung Kim, Jang-Whan Bae, Sang Yeub Lee, Sung Uk Kwon, Je Sang Kim, Jin-Ok Jeong, Seong-Hoon Lim, Sungsoo Cho, Jeong Hoon Yang, Hyeon-Cheol Gwon
Journal: Journal of the American College of Cardiology (2022)
Screening for Hypertension in Children With and Without Autism Spectrum Disorder
Authors: James T. Nugent, Christine Bakhoum, Lama Ghazi, Jason H. Greenberg
Journal: JAMA Network Open (2022)

ResultsOf 44 501 visits, 0.5% (95% CI, 0.4%-0.7%)involved children with autism, with median (IQR) age in years (11 [6-18] vs 12 [6-17]), median (IQR) previous visits in past year (1 [0-2] vs 2 [1-4]), and visits with an obesity diagnosis (4.8% [95% CI, 1.6%-13.7%]vs 4.0% [95% CI, 3.6%-4.5%])similar for visits with and without an autism diagnosis; visits with autism involved more males (80.8% [95% CI, 69.4%-88.6%]vs 41.7% [40.3%-43.2%]).HS occurred in 55.8% (95% CI, 37.3%-72.8%) of visits with autism vs 75.7% (95% CI, 74.1%-77.2%)without autism (P = .02)(Figure).When divided into 2 periods, HS increased over time for children without autism but not for children with autism.HS for children with other conditions occurred at least as often as for children without that condition.Among visits with BP measured, hypertensive readings 3 occurred in 16.7% (95% CI, 7.9-31.8)with
Department of Error
Journal: The Lancet (2022)

Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 2022; 399: 924–44—In this Article, in table 4, in the first column, the fifth row should read “Infection-derived, immunity increases among people who are unvaccinated”. The appendix has also been corrected. These corrections have been made to the online version as of April 4, 2022.
TCTAP A-054 Shockwave Intravascular Lithotripsy as a Novel Strategy for the Treatment of Stent Underexpansion Caused by Calcified Plaques
Authors: Wojciech Wańha, Mariusz Tomaniak, Jacek Bil, Rafał Januszek, Rafał Wolny, Maksymilian Opolski, Łukasz Kuźma, Adam Janas, Tomasz Figatowski, Łukasz Lewicki, Jakub Kulczycki, Adrian Wlodarczak, Brunon Tomasiewicz, Sylwia Iwańczyk, Jerzy Sacha, Łukasz Koltowski, Miłosz Dziarmaga, Miłosz Jaguszewski, Bartosz Olajossy, Krzysztof Dyrbuś, Krzysztof Reczuch, Robert Gil, Sławomir Dobrzycki, Janusz Kochman, Andrzej Ochala, Adam Witkowski, Maciej Lesiak, Fabrizio D'Ascenzo, Sławomir Bartuś, Wojciech Wojakowski
Journal: Journal of the American College of Cardiology (2022)
TCTAP C-088 The Road Less Traveled: Rotational Atherectomy of the Left Anterior Descending and Left Circumflex Arteries in a Heavily Calcified and Critical True Left Main Bifurcation on the Background of Non-ST Elevation Myocardial Infarction With Cardiogenic Shock Using Double Guiding Catheter
Authors: Kristy Brillantes Garganera, Bryan Rene Toledano, Francis Charles Fernandez, Michelangelo L. Sabas
Journal: Journal of the American College of Cardiology (2022)
TCTAP A-080 Effects of High-Sensitivity C-reactive Protein on Lipoprotein(a)-Associated Cardiovascular Mortality Risk in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
Authors: Deshan Yuan, Peizhi Wang, Sida Jia, Ce Zhang, Runlin Gao, Jinqing Yuan
Journal: Journal of the American College of Cardiology (2022)
JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes
Authors: Léa Sureau, Caroline Buors, Jean-Christophe Ianotto, Françoise Boyer, Aline Tanguy-Schmidt, Lydia Roy, Emilie Cayssials, Laura Cailly, Jean-Claude Chomel, Aurélie Chauveau, Corentin Orvain, Olivier Mansier, Dana Ranta, Margot Robles, Emmanuel Gyan, Olivier Hérault, Stanislas Nimubona, Tony Marchand, Eric Lippert, Jérémie Riou, Valérie Ugo, Damien Luque Paz
Journal: Blood Cancer Journal (2022)
HIV-1-infection in a man who has sex with men despite self-reported excellent adherence to pre-exposure prophylaxis, the Netherlands, August 2021: be alert to emtricitabine/tenofovir-resistant strain transmission
Authors: Jeffrey CD Koole, Feline de la Court, Matthijs RA Welkers, Kenneth Yap, Janneke E Stalenhoef, Suzanne Jurriaans, Henry JC de Vries, Eline LM Op de Coul, Maria Prins, Elske Hoornenborg
Journal: Eurosurveillance (2022)

In August 2021, a man who has sex with men was diagnosed with HIV-1 infection despite using event-driven pre-exposure prophylaxis for over 2 years with self-reported excellent adherence. Sequencing identified resistance-associated mutations (RAM) M184V and K65R, conferring resistance to emtricitabine and tenofovir, and RAM V108I and E138A. Background RAM prevalence was two of 164 (1.2%) new HIV diagnoses in Amsterdam (2017-19). We reiterate the need for frequent HIV testing among PrEP users and additional testing in case of symptoms.
TCTAP A-025 "Do Women Truly Have Worst Outcomes?" Comparison of Outcome Differences for Percutaneous Coronary Intervention in Unprotected Left Main Disease - A Propensity Matched Analysis
Authors: Mugilan Sundarajoo, Quah Wy Jin, Kumara Gurupparan Ganesan, Jayakhanthan Kolanthaivelu, David Yong, Kogulakrishnan Kaniappan, Low Ming Yoong
Journal: Journal of the American College of Cardiology (2022)